MaxCyte (MXCT) vs TransMedics Group (TMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TransMedics Group (TMDX) has outperformed MaxCyte (MXCT) over the past year, losing 33.1% versus a loss of 40.0%. Over five years, TMDX leads with a +197.6% price change compared with -90.8% for MXCT. TransMedics Group is the larger company by market cap ($2.74 billion vs $105.3 million), about 26.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MXCT | TMDX |
|---|---|---|
| Share price | $1.02 | $79.00 |
| Market cap | $105.27M | $2.74B |
| 1-day change | -1.92% | -2.55% |
| YTD return | -34.19% | -35.06% |
| 1-year return | -40.00% | -33.08% |
| 5-year return | -90.75% | +197.55% |
| P/E ratio (TTM) | — | 20.47 |
| Forward P/E | — | 35.05 |
| EPS (TTM) | $-0.34 | $3.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $605.49M |
| Revenue growth (YoY) | — | +37.13% |
| Net income (latest FY) | — | $190.29M |
| Gross margin | — | 59.92% |
| Operating margin | — | 17.93% |
| Net margin | — | 31.43% |
| 52-week high | $1.87 | $156.00 |
| 52-week low | $0.643 | $60.11 |
| Distance from 52-week high | -45.31% | -49.36% |
| Analyst consensus | none | buy |
| Avg. price target upside | +302.94% | +26.35% |
| Average volume | 668.82K | 820.41K |
| Shares outstanding | 103.21M | 34.68M |
| Employees | 91 | 898 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TransMedics Group is about 26.0 times larger than MaxCyte by market value ($2.74B vs $105.27M).
About MaxCyte
MXCT stock →MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.
Healthcare · Medical Devices · 91 employees
About TransMedics Group
TMDX stock →TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
Healthcare · Medical Devices · 898 employees
MXCT vs TMDX FAQ
Which is bigger, MaxCyte or TransMedics Group?
TransMedics Group (TMDX) is larger, with a market capitalization of $2.74B compared with $105.27M for MaxCyte (MXCT).
Which stock has performed better over the past year, MXCT or TMDX?
TMDX returned -33.08% over the past 12 months, compared with -40.00% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are MaxCyte and TransMedics Group in the same industry?
Yes. Both are classified in the Medical Devices industry within the Healthcare sector.